Akcea
Alnylam to file rare kidney disease drug after trial win
Richard Staines
Akcea, Alnylam, Rare diseases, RNA interference
0 Comment
Pfizer inks deal with Ionis and Akcea for potential blockbuster diabetes and NASH drug
Richard Staines
Akcea, Diabetes, Ionis, NASH, Pfizer
0 Comment
Ionis’ FCS drug approved in EU, launch due in Germany
Richard Staines
Akcea, Ionis Pharmaceuticals, market access, ultra-rare diseases
0 Comment
NICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okay
Phil Taylor
Akcea, Alnylam, hATTR, market access, NICE, Rare diseases
0 Comment
Akcea/Ionis’ rare disease drug Waylivra set for EU market after rejection in US
Richard Staines
Akcea, familial chylomicronemia syndrome, Ionis, Rare diseases
0 Comment
Novartis licenses lipoprotein-lowering CVD drug
George Underwood
Akcea, cardiovascular, CVD, Ionis, Novartis
0 Comment